EGFR ( Epidermal Growth Factor Receptor) is a protein involved in cell growth and division. Mutations in the EGFR gene, such as deletions and point mutations, can contribute to the development and progression of cancers. The exon19 deletion and T790M mutation are known to be associated with resistance to some EGFR tyrosine kinase inhibitors (TKIs). Signosis has launched the EGFR del19 (746-750) & T790M expressing Ba/F3 cell line, which expresses EGFR with the most common exon 19 deletion (AA 746-750) and T790M mutations. This cell line is valuable for understanding the complexity of EGFR mutations in cancer and for testing potential therapeutic strategies, especially in the context of drug resistance mechanisms. Researchers can use these cell lines to study how cancer cells with these specific mutations respond to various treatments, aiding in the development of more effective targeted therapies.
 
This cell line was established by electroporation to transfect Ba/F3 cells a vector containing the EGFR del19 (746-750) & T790M gene with GFP and hygromycin resistance. Clones with resistance to hygroymcin were subsequently screened for GFP expression, with protein expression of the mutant EGFR tested via western blot. The clone with the highest expression were selected and expanded to produce this stable cell line.